Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
CG Oncology, Inc. - Common stock
(NQ:
CGON
)
71.85
+2.35 (+3.38%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 17, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,058,944
Open
68.72
Bid (Size)
62.00 (200)
Ask (Size)
76.50 (100)
Prev. Close
69.50
Today's Range
68.72 - 72.92
52wk Range
23.65 - 77.00
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
CG Oncology Eyes Bladder Cancer Breakthrough With Phase 3 Data, Q4 Filing Ahead
↗
June 10, 2026
CG Oncology (NASDAQ:CGON) Chief Executive Officer Arthur outlined the company’s upcoming clinical and regulatory milestones for cretostimogene during a presentation at the Goldman Sachs Global...
Via
MarketBeat
Topics
Initial Public Offering
CG Oncology Touts Cretostimogene Data, BLA Progress in Bladder Cancer Push
↗
June 07, 2026
CG Oncology (NASDAQ:CGON) is focused on advancing cretostimogene, an oncolytic immunotherapy for non-muscle invasive bladder cancer, Chief Executive Officer Arthur Kuan said during a discussion at the...
Via
MarketBeat
Topics
Initial Public Offering
Performance
YTD
+71.9%
+71.9%
1 Month
+18.9%
+18.9%
3 Month
-2.2%
-2.2%
6 Month
+31.3%
+31.3%
1 Year
+152.5%
+152.5%
More News
Read More
CG Oncology to Present at Upcoming Investor Conferences in June
May 28, 2026
From
CG Oncology Inc.
Via
GlobeNewswire
CG Oncology Touts Bladder Cancer Data, Q4 Filing Plans at RBC Conference
↗
May 20, 2026
Via
MarketBeat
Topics
Initial Public Offering
CG Oncology Inc (NASDAQ:CGON) Shows Perfect Technical Rating and Strong Setup Quality for Potential Breakout
↗
May 11, 2026
Via
Chartmill
SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
May 19, 2026
From
CG Oncology Inc.
Via
GlobeNewswire
CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients
May 15, 2026
From
CG Oncology Inc.
Via
GlobeNewswire
CG Oncology BLA Filing on Track as Key Bladder Cancer Data Nears
↗
May 15, 2026
Via
MarketBeat
Topics
Initial Public Offering
CG Oncology’s Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC
May 11, 2026
From
CG Oncology Inc.
Via
GlobeNewswire
CG Oncology Analysts Boost Their Forecasts Following Q1 Earnings
↗
May 11, 2026
Via
Benzinga
CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates
May 08, 2026
From
CG Oncology Inc.
Via
GlobeNewswire
CG Oncology to Present at Upcoming Investor Conferences in May
May 05, 2026
From
CG Oncology Inc.
Via
GlobeNewswire
As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors?
↗
March 23, 2026
Via
The Motley Fool
This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know
↗
March 21, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
ImmunityBio (IBRX) Shares Plummet Despite Piper Sandler Price Target Hike and 700% Revenue Growth
March 04, 2026
Via
MarketMinute
Topics
Earnings
Economy
CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates
February 27, 2026
From
CG Oncology Inc.
Via
GlobeNewswire
CG Oncology to Present at the TD Cowen 46th Annual Health Care Conference
February 23, 2026
From
CG Oncology Inc.
Via
GlobeNewswire
CG Oncology Soars 102% in a Year, but One Investor Just Disclosed a $58.5 Million Sale
↗
February 19, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
ASCO GU 2026: Merck and Protara Poised to Disrupt Bladder and Kidney Cancer Standards
February 16, 2026
Via
MarketMinute
Topics
Intellectual Property
What's going on in today's session
↗
January 09, 2026
Via
Chartmill
Keep an eye on the top gainers and losers in Friday's session.
↗
January 09, 2026
Via
Chartmill
CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC
January 09, 2026
From
CG Oncology Inc.
Via
GlobeNewswire
CG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 06, 2026
From
CG Oncology Inc.
Via
GlobeNewswire
This Biotech Fund Exited an $8 Million Edgewise Stake as the Stock Slid Double Digits
↗
December 29, 2025
Via
The Motley Fool
SUO-CTC and CG Oncology Announce the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
December 18, 2025
From
CG Oncology Inc.
Via
GlobeNewswire
Frequently Asked Questions
Is CG Oncology, Inc. - Common stock publicly traded?
Yes, CG Oncology, Inc. - Common stock is publicly traded.
What exchange does CG Oncology, Inc. - Common stock trade on?
CG Oncology, Inc. - Common stock trades on the Nasdaq Stock Market
What is the ticker symbol for CG Oncology, Inc. - Common stock?
The ticker symbol for CG Oncology, Inc. - Common stock is CGON on the Nasdaq Stock Market
What is the current price of CG Oncology, Inc. - Common stock?
The current price of CG Oncology, Inc. - Common stock is 71.85
When was CG Oncology, Inc. - Common stock last traded?
The last trade of CG Oncology, Inc. - Common stock was at 07/17/26 04:00 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
